U.S. Neuromodulation Market Overview
The United States neuromodulation market size was valued at USD 1,808 Million in 2023 and estimates the market to reach USD 3,868 Million by 2032, exhibiting a CAGR of 8.1% from 2024-2032.
Neuromodulation is defined by the International Neuromodulation Society (INS) as a field of science, medicine, and bioengineering that encompasses implantable and non-implantable technologies, electrical or chemical, that impact upon neural interfaces to improve life for humanity. Neurological disorders such as epilepsy, Alzheimer's disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous systems. Neuromodulation is used to manage such disorders.
The U.S. Neuromodulation Market is mainly driven by the increasing incidence of neurological diseases, such as Alzheimer’s and Parkinson’s diseases across the world. According to World Health Organization, worldwide, around 50 million people have dementia, and there are nearly 10 million new cases every year. Alzheimer's disease is the most common form of dementia and may contribute to 60–70% of cases. Moreover, other factors such as the rising old age population and their vulnerability for neurological disorders and growing awareness regarding the safety and efficacy of neurostimulator devices are remarkably contributing to the growth of the U.S. Neuromodulation Market.
On the other hand, lack of trained healthcare professionals and stringent approval policies, are expected to hamper the growth of the market.
Covid-19 Impact on U.S. Neuromodulation Market
In addition, the current U.S. Neuromodulation Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Neuromodulation Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2023 and its projection up to 2032 is provided in detail in this report.
U.S Neuromodulation Market Segment Overview
According to technology, the Spinal Cord Stimulation segment has significant growth in the Neuromodulation market. The spinal cord stimulation (SCS) has huge potential to treat widespread chronic back pain. Around 20% of adult Americans experience chronic pain. Recently, USFDA and similar regulatory agencies have approved many products of the SCS technology. The use of technology is expanding to new indications such as failed back surgery syndrome, refractory angina pectoris, peripheral vascular disease, and complex regional pain syndrome. Additionally, Deep Brain Stimulation (DBS) segment is expected to show noteworthy growth owing to the high adoption rate in developed countries for neurological disorders, such as Parkinson’s disease. The use of DBS is mainly in severe obsessive-compulsive disorder, treatment-resistant depression, Alzheimer's type dementia, and movement disorders.
Neuromodulation Market, By Technology
- Internal neuromodulation
- Deep Brain Stimulation
- Sacral Nerve Stimulation
- Vagus Nerve Stimulation
- Spinal Cord Stimulation
- Other Neuromodulation Technologies
- External neuromodulation
- Transcutaneous Electrical Nerve Stimulation
- Transcranial Magnetic Stimulation
Neuromodulation Market, By Application
· Chronic Pain Management
· Failed back syndrome
· Epilepsy
· Tremor
· Urinary and Fecal Incontinence
· Depression
· Dystonia
· Gastroparesis
· Parkinson's disease
· Obsessive-Compulsive Disorder
· Migraine
· Other
Neuromodulation Market, By Biomaterial
· Metallic Biomaterials
· Polymeric Biomaterials
· Ceramic Biomaterials
U.S. Neuromodulation Regional Overview
Region-wise, North America is the most significant region in the neuromodulation market and is anticipated to be the first preference for new competitors due to the increasing end-use in the region. Similarly, the market in the Asia Pacific is anticipated to expand at a rapid pace in the coming years. Factors such as government and private initiatives to increase awareness regarding mental health and increasing incidences of neurological disorders boost the market’s growth in the Asia Pacific. In addition to this, Japan has the highest revenue share in the region, followed by China. India is expected to witness rapid growth in the future due to increasing awareness regarding mental disorders and growing expenditure in the healthcare sector.
Neuromodulation Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
U.S. Neuromodulation Market Competitor Overview
Some key developments and strategies adopted by manufacturers in Neuromodulation are highlighted below.
· In July 2021, Merck KGaA has tapped a Spanish startup to help it build a new approach to bioelectronic therapies. The aim is to use graphene to target multiple chronic diseases through selective nerve stimulation.
U.S. Neuromodulation Market, Key Players
· Medtronic plc
· St. Jude Medical, Inc.
· LivaNova PLC
· Boston Scientific Corporation
· Aleva Neurotherapeutics SA
· BioControl Medical
· Bioness Inc.
· EnteroMedics Inc
· Nevro Corporation and NeuroPace Inc.
Neuromodulation Market Study Global Market Analysis, Insights and Forecast, 2020-2027 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1. Key Emerging Trends – For Major Countries 4.2. Latest Technological Advancement 4.3. Regulatory Landscape 4.4. Industry SWOT Analysis 4.5. Porters Five Forces Analysis 5. Global Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027 5.1. Key Findings / Summary 5.2. Market Analysis, Insights and Forecast – By Technology 5.2.1. Internal neuromodulation 5.2.1.1. Deep Brain Stimulation 5.2.1.2. Sacral Nerve Stimulation 5.2.1.3. Vagus Nerve Stimulation 5.2.1.4. Spinal Cord Stimulation 5.2.1.5. Other Neuromodulation Technologies 5.2.2. External neuromodulation 5.2.2.1. Transcutaneous Electrical Nerve Stimulation 5.2.2.2. Transcranial Magnetic Stimulation 5.3. Market Analysis, Insights and Forecast – By Application 5.3.1. Chronic Pain Management 5.3.2. Failed back syndrome 5.3.3. Epilepsy 5.3.4. Tremor 5.3.5. Urinary and Fecal Incontinence 5.3.6. Depression 5.3.7. Dystonia 5.3.8. Gastroparesis 5.3.9. Parkinson's disease 5.3.10. Obsessive-Compulsive Disorder 5.3.11. Migraine 5.3.12. Other 5.4. Market Analysis, Insights and Forecast – By Biomaterial 5.4.1. Metallic Biomaterials 5.4.2. Polymeric Biomaterials 5.4.3. Ceramic Biomaterials 5.5. Market Analysis, Insights and Forecast – By Region 5.5.1. North America 5.5.2. Europe 5.5.3. Asia Pacific 5.5.4. Latin America, Middle East and Africa 6. North America Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027 6.1. Key Findings / Summary 6.2. Market Analysis, Insights and Forecast – By Technology 6.2.1. Internal neuromodulation 6.2.1.1. Deep Brain Stimulation 6.2.1.2. Sacral Nerve Stimulation 6.2.1.3. Vagus Nerve Stimulation 6.2.1.4. Spinal Cord Stimulation 6.2.1.5. Other Neuromodulation Technologies 6.2.2. External neuromodulation 6.2.2.1. Transcutaneous Electrical Nerve Stimulation 6.2.2.2. Transcranial Magnetic Stimulation 6.3. Market Analysis, Insights and Forecast – By Application 6.3.1. Chronic Pain Management 6.3.2. Failed back syndrome 6.3.3. Epilepsy 6.3.4. Tremor 6.3.5. Urinary and Fecal Incontinence 6.3.6. Depression 6.3.7. Dystonia 6.3.8. Gastroparesis 6.3.9. Parkinson's disease 6.3.10. Obsessive-Compulsive Disorder 6.3.11. Migraine 6.3.12. Other 6.4. Market Analysis, Insights and Forecast – By Biomaterial 6.4.1. Metallic Biomaterials 6.4.2. Polymeric Biomaterials 6.4.3. Ceramic Biomaterials 6.5. Market Analysis, Insights and Forecast – By Country 6.5.1. U.S. 6.5.2. Canada 7. Europe Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027 7.1. Key Findings / Summary 7.2. Market Analysis, Insights and Forecast – By Technology 7.2.1. Internal neuromodulation 7.2.1.1. Deep Brain Stimulation 7.2.1.2. Sacral Nerve Stimulation 7.2.1.3. Vagus Nerve Stimulation 7.2.1.4. Spinal Cord Stimulation 7.2.1.5. Other Neuromodulation Technologies 7.2.2. External neuromodulation 7.2.2.1. Transcutaneous Electrical Nerve Stimulation 7.2.2.2. Transcranial Magnetic Stimulation 7.3. Market Analysis, Insights and Forecast – By Application 7.3.1. Chronic Pain Management 7.3.2. Failed back syndrome 7.3.3. Epilepsy 7.3.4. Tremor 7.3.5. Urinary and Fecal Incontinence 7.3.6. Depression 7.3.7. Dystonia 7.3.8. Gastroparesis 7.3.9. Parkinson's disease 7.3.10. Obsessive-Compulsive Disorder 7.3.11. Migraine 7.3.12. Other 7.4. Market Analysis, Insights and Forecast – By Biomaterial 7.4.1. Metallic Biomaterials 7.4.2. Polymeric Biomaterials 7.4.3. Ceramic Biomaterials 7.5. Market Analysis, Insights and Forecast – By Country 7.5.1. UK 7.5.2. Germany 7.5.3. France 7.5.4. Italy 7.5.5. Spain 7.5.6. Russia 7.5.7. Rest of Europe 8. Asia Pacific Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027 8.1. Key Findings / Summary 8.2. Market Analysis, Insights and Forecast – By Technology 8.2.1. Internal neuromodulation 8.2.1.1. Deep Brain Stimulation 8.2.1.2. Sacral Nerve Stimulation 8.2.1.3. Vagus Nerve Stimulation 8.2.1.4. Spinal Cord Stimulation 8.2.1.5. Other Neuromodulation Technologies 8.2.2. External neuromodulation 8.2.2.1. Transcutaneous Electrical Nerve Stimulation 8.2.2.2. Transcranial Magnetic Stimulation 8.3. Market Analysis, Insights and Forecast – By Application 8.3.1. Chronic Pain Management 8.3.2. Failed back syndrome 8.3.3. Epilepsy 8.3.4. Tremor 8.3.5. Urinary and Fecal Incontinence 8.3.6. Depression 8.3.7. Dystonia 8.3.8. Gastroparesis 8.3.9. Parkinson's disease 8.3.10. Obsessive-Compulsive Disorder 8.3.11. Migraine 8.3.12. Other 8.4. Market Analysis, Insights and Forecast – By Biomaterial 8.4.1. Metallic Biomaterials 8.4.2. Polymeric Biomaterials 8.4.3. Ceramic Biomaterials 8.5. Market Analysis, Insights and Forecast – By Country 8.5.1. China 8.5.2. India 8.5.3. Japan 8.5.4. Australia 8.5.5. South East Asia 8.5.6. Rest of Asia Pacific 9. Latin America, Middle East and Africa Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027 9.1. Key Findings / Summary 9.2. Market Analysis, Insights and Forecast – By Technology 9.2.1. Internal neuromodulation 9.2.1.1. Deep Brain Stimulation 9.2.1.2. Sacral Nerve Stimulation 9.2.1.3. Vagus Nerve Stimulation 9.2.1.4. Spinal Cord Stimulation 9.2.1.5. Other Neuromodulation Technologies 9.2.2. External neuromodulation 9.2.2.1. Transcutaneous Electrical Nerve Stimulation 9.2.2.2. Transcranial Magnetic Stimulation 9.3. Market Analysis, Insights and Forecast – By Application 9.3.1. Chronic Pain Management 9.3.2. Failed back syndrome 9.3.3. Epilepsy 9.3.4. Tremor 9.3.5. Urinary and Fecal Incontinence 9.3.6. Depression 9.3.7. Dystonia 9.3.8. Gastroparesis 9.3.9. Parkinson's disease 9.3.10. Obsessive-Compulsive Disorder 9.3.11. Migraine 9.3.12. Other 9.4. Market Analysis, Insights and Forecast – By Biomaterial 9.4.1. Metallic Biomaterials 9.4.2. Polymeric Biomaterials 9.4.3. Ceramic Biomaterials 9.5. Market Analysis, Insights and Forecast – By Country 9.5.1. Brazil 9.5.2. Saudi Arabia 9.5.3. UAE 9.5.4. Rest of LAMEA 10. Competitive Analysis 10.1. Company Market Share Analysis, 2018 10.2. Key Industry Developments 10.3. Company Profile 10.4. Medtronic plc 10.4.1. Business Overview 10.4.2. Segment 1 & Service Offering 10.4.3. Overall Revenue 10.4.4. Geographic Presence 10.4.5. Recent Development *Similar details will be provided for the following companies 10.5. St. Jude Medical, Inc. 10.6. LivaNova PLC 10.7. Boston Scientific Corporation 10.8. Aleva Neurotherapeutics SA 10.9. BioControl Medical 10.10. Bioness Inc. 10.11. EnteroMedics Inc 10.12. Nevro Corporation and NeuroPace Inc.
<p>List of Figures Figure 1: Global Neuromodulation Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027 Figure 2: Global Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027 Figure 3: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 4: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 5: Global Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027 Figure 6: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 7: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 8: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 9: Global Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 10: Global Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027 Figure 11: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 12: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 13: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 14: Global Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 15: Global Neuromodulation Market Value (USD Billion), by Region, 2019 & 2027 Figure 16: North America Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027 Figure 17: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 18: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 19: North America Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027 Figure 20: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 21: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 22: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 23: North America Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 24: North America Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027 Figure 25: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 26: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 27: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 28: North America Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 29: North America Neuromodulation Market Forecast (USD Billion), by U.S., 2016-2027 Figure 30: North America Neuromodulation Market Forecast (USD Billion), by Canada, 2016-2027 Figure 31: Latin America Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027 Figure 32: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 33: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 34: Latin America Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027 Figure 35: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 36: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 37: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 38: Latin America Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 39: Latin America Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027 Figure 40: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 41: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 42: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 43: Latin America Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 44: Latin America Neuromodulation Market Forecast (USD Billion), by Brazil, 2016-2027 Figure 45: Latin America Neuromodulation Market Forecast (USD Billion), by Mexico, 2016-2027 Figure 46: Latin America Neuromodulation Market Forecast (USD Billion), by Rest of Latin America, 2016-2027 Figure 47: Europe Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027 Figure 48: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 49: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 50: Europe Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027 Figure 51: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 52: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 53: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 54: Europe Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 55: Europe Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027 Figure 56: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 57: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 58: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 59: Europe Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 60: Europe Neuromodulation Market Forecast (USD Billion), by U.K., 2016-2027 Figure 61: Europe Neuromodulation Market Forecast (USD Billion), by Germany, 2016-2027 Figure 62: Europe Neuromodulation Market Forecast (USD Billion), by France, 2016-2027 Figure 63: Europe Neuromodulation Market Forecast (USD Billion), by Italy, 2016-2027 Figure 64: Europe Neuromodulation Market Forecast (USD Billion), by Spain, 2016-2027 Figure 65: Europe Neuromodulation Market Forecast (USD Billion), by Russia, 2016-2027 Figure 66: Europe Neuromodulation Market Forecast (USD Billion), by Rest of Europe, 2016-2027 Figure 67: Asia Pacific Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027 Figure 68: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 69: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 70: Asia Pacific Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027 Figure 71: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 72: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 73: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 74: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 75: Asia Pacific Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027 Figure 76: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 77: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 78: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 79: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 80: Asia Pacific Neuromodulation Market Forecast (USD Billion), by China, 2016-2027 Figure 81: Asia Pacific Neuromodulation Market Forecast (USD Billion), by India, 2016-2027 Figure 82: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Japan, 2016-2027 Figure 83: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Australia, 2016-2027 Figure 84: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Southeast Asia, 2016-2027 Figure 85: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027 Figure 86: Middle East & Africa Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027 Figure 87: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 88: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 89: Middle East & Africa Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027 Figure 90: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 91: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 92: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 93: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 94: Middle East & Africa Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027 Figure 95: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027 Figure 96: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027 Figure 97: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027 Figure 98: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027 Figure 99: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by GCC, 2016-2027 Figure 100: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by South Africa, 2016-2027 Figure 101: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027  List of Tables Table 1: Global Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027 Table 2: Global Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027 Table 3: Global Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027 Table 4: Global Neuromodulation Market Revenue (USD Billion) Forecast, by Region, 2016-2027 Table 5: North America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027 Table 6: North America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027 Table 7: North America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027 Table 8: North America Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027 Table 9: Europe Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027 Table 10: Europe Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027 Table 11: Europe Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027 Table 12: Europe Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027 Table 13: Latin America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027 Table 14: Latin America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027 Table 15: Latin America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027 Table 16: Latin America Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027 Table 17: Asia Pacific Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027 Table 18: Asia Pacific Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027 Table 19: Asia Pacific Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027 Table 20: Asia Pacific Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027 Table 21: Middle East & Africa Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027 Table 22: Middle East & Africa Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027 Table 23: Middle East & Africa Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027 Table 24: Middle East & Africa Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027</p>
Research Process
Data Library Research are conducted by industry experts who offer insight on
industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager
and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Primary Research
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size Estimation
Both, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
